Health ❯ Healthcare ❯ Drug Development

Pharmaceuticals

Simufilam AI in Healthcare New Drug Application Spleen Tyrosine Kinase Inhibitors Gene Therapy Cardiac Sarcomere Modulators

Alumis TYK2 Pill Hits Phase 3 Goals in Psoriasis as Stock Jumps and $175 Million Offering Is Planned

The company moves to raise $175 million following the readout, signaling plans for an FDA filing in the second half of 2026.

Edgewise Reports Favorable Interim Safety in Phase 2 HCM Trial of EDG-7500

Sarepta Shares Plunge After ESSENCE Phase 3 Miss in Duchenne Trial

ArcaScience Raises $7 Million Seed to Expand AI Drug Benefit–Risk Platform

Cassava Sciences Halts Alzheimer’s Drug Trials Following Phase 3 Failure